Ghobadi Hassan, Mokhtari Sara, Aslani Mohammad Reza
Department of Internal Medicine, Division of Pulmonary, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Lung Inflammatory Diseases Research Center, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
J Res Med Sci. 2021 Feb 27;26:17. doi: 10.4103/jrms.JRMS_626_19. eCollection 2021.
Visfatin is an adipokine that increased under inflammatory conditions. Moreover, sirtuin-1 possesses regulatory effects on inflammatory factors. In this study, we aimed to evaluate the serum level of visfatin in patients with stable and acute exacerbation of chronic obstructive pulmonary disease (AE-COPD).
In a case-control study, thirty patients with stable COPD (S-COPD), thirty patients with AE-COPD, and thirty control subjects were enrolled. Pulmonary function tests and blood sampling were performed on all participants. Serum visfatin, sirtuin-1, and interleukin (IL)-6 levels were measured using the sandwich ELISA method and assessed their association with study parameters.
The findings of the current study revealed that serum levels of visfatin in AE-COPD patients were higher than those of healthy controls and S-COPD (for healthy control; standardized mean difference [SMD] = 2.63, 95% confidence interval [CI] =1.31-2.83, < 0.001, and for S-COPD; SMD = 1.53, 95% CI = 0.21-2.85, < 0.05). On the other hand, the serum levels of sirtuin-1 were higher in healthy controls compared to the S-COPD and AE-COPD patients (for S-COPD; SMD = 1.56, 95% CI = 0.018-3.11, < 0.05, for AE-COPD; SMD = 1.50, 95% CI = 0.048-3.04, < 0.05).
Elevated visfatin and IL-6 levels demonstrated their pro-inflammatory effects in patients with COPD, especially in AE-COPD patients. In addition, the negative association found between serum visfatin and sirtuin-1 levels suggested the pathophysiologic and therapeutic roles of these factors in COPD patients.
内脂素是一种在炎症状态下升高的脂肪因子。此外，沉默调节蛋白-1对炎症因子具有调节作用。在本研究中，我们旨在评估慢性阻塞性肺疾病稳定期和急性加重期（AE-COPD）患者的血清内脂素水平。
在一项病例对照研究中，纳入了30例稳定期慢性阻塞性肺疾病（S-COPD）患者、30例AE-COPD患者和30例对照受试者。对所有参与者进行肺功能测试和血液采样。采用夹心酶联免疫吸附测定法测量血清内脂素、沉默调节蛋白-1和白细胞介素（IL）-6水平，并评估它们与研究参数的相关性。
本研究结果显示，AE-COPD患者的血清内脂素水平高于健康对照和S-COPD患者（与健康对照相比；标准化均值差[SMD]=2.63，95%置信区间[CI]=1.31-2.83，<0.001；与S-COPD患者相比；SMD=1.53，95%CI=0.21-2.85，<0.05）。另一方面，健康对照的血清沉默调节蛋白-1水平高于S-COPD和AE-COPD患者（与S-COPD患者相比；SMD=1.56，95%CI=0.018-3.11，<0.05；与AE-COPD患者相比；SMD=1.50，95%CI=0.048-3.04，<0.05）。
内脂素和IL-6水平升高表明它们在COPD患者中具有促炎作用，尤其是在AE-COPD患者中。此外，血清内脂素与沉默调节蛋白-1水平之间的负相关表明这些因子在COPD患者中的病理生理和治疗作用。
